Survival outcomes in ALK-positive NSCLC patients (p) treated 1st line brigatinib and impact of the ALK fusion variant-MedSci.cn

Survival outcomes in ALK-positive NSCLC patients (p) treated 1st line brigatinib and impact of the ALK fusion variant

Provencio-Pulla, M; Campelo, RG; Azkarate, A; Calvo, V; Cobo, M; Mosquera, JPI; Nadal, E; Rodriguez-Abreu, D; Fabregat, RM; Callejo, A; Domine, M; Juan-Vidal, O; Garcia-Garcia, F; Sanchez, E; Romero, A

JOURNAL OF CLINICAL ONCOLOGY, 2023; 41 (16):

科室
- - 订阅+
  - 更多科室
工具
服务